← Back to patent-cliff list
AZD-1656
Tier C — Watch / tradeAZD-1656
AstraZeneca
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GK
Indications (approved)：Type 2 diabetes, Kidney transplant rejection, End-stage renal disease, COVID-19, 高血糖症, Type 1 diabetes
Regional status
US
No progress
2009-01-01
EU
Phase II
2009-10-01
China
-
Japan
No progress
2010-05-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AZD-1656?
Approved indications include: Type 2 diabetes, Kidney transplant rejection, End-stage renal disease, COVID-19, 高血糖症, Type 1 diabetes.
When does the AZD-1656 patent expire?
No public expiry year is available for AZD-1656 yet; this page updates once verified.
How do I get a quote for AZD-1656 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21